A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

606

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions

TNBC - Triple-Negative Breast Cancer

Interventions

DRUG

epirubicin,cyclophosphamide,paclitaxel,Carrelizumab

Conventional chemotherapy in combination with carrelizumab

DRUG

epirubicin,cyclophosphamide,paclitaxel

Conventional chemotherapy

Trial Locations (1)

RECRUITING

Breast cancer institute of Fudan University Cancer Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER